Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.06.24.734366

Longitudinal proteomic module configurations differ across human monocyte-derived differentiation and polarization conditions

Abstract

Human monocyte differentiation involves changes in multiple protein programs, but comparisons across culture conditions can conflate source variation with differentiation time. We reanalyzed public proteomic measurements arranged in four source blocks across M1-polarizing, M2-polarizing, dendritic-cell and osteoclast conditions at days 2, 4, 6, 8 and 10. The original experiment used three individual-donor preparations and one preparation pooled from 40 donors; these are not four individual donors. Eight predefined protein-module scores formed an 80-observation matrix. A multivariate model tested joint condition and condition-by-time terms beyond source block and categorical time, using 9,999 permutations that preserved complete block-specific culture trajectories. The joint condition terms accounted for an additional 31.37% of total module-score variation (pseudo-F = 4.257567; permutation p = 0.0002). The association persisted after omission of each source block, with incremental R-squared of 0.315-0.390. Secondary day-specific tests detected differences at days 4-10, whereas day 2 did not meet the false-discovery criterion. Descriptive trajectories showed a shared increase in glycolysis/pentose-phosphate scores alongside condition-dependent mitochondrial, redox and proteostasis profiles. At day 10, M2-labelled cultures had the lowest mean mitochondrial score, whereas M1-labelled cultures had the highest three-protein resolution-associated score. All eight module tests survived multiplicity correction, and no single-module omission abolished the multivariate association. These findings describe condition-associated configurations within four heterogeneous source preparations. Equal weighting of source blocks does not estimate a mean across individual donors. The analysis does not establish pathway activity, single-cell trajectories, population-level replication or external biological validation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Navarro Quiroz, R., Escorcia Lindo, K., Jaruffe Pinilla, A., Luna-Rodriguez, I. K., Diaz-Olmos, Y., Geribaldi-Doldan, N., Fernandez-Ponce, C., Zarate Penate, E., Bello Lemus, Y., Pacheco Lugo, L., Pacheco Londono, L., Acosta-Hoyos, A., Navarro Quiroz, E.. 2026-06-26. Longitudinal proteomic module configurations differ across human monocyte-derived differentiation and polarization conditions. https://doi.org/10.64898/2026.06.24.734366

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Melanoma suppresses galectin-9-glycan axis in dendritic cells and galectin-9 restoration limits T regulatory cell expansion

Dendritic cells (DCs) are key orchestrators of anti-tumor adaptive immune responses. Their function is tightly regulated by galectins, a family of carbohydrate-biding proteins that decode extracellular glycans into intracellular signaling. Here, we show that exposure to melanoma-conditioned media (CM) induces loss of galectin-9 (gal-9) at the DC surface. Notably, gal-9 loss, independent of transcriptional regulation, was associated with the acquisition of an immunosuppressive phenotype in CD14cDC2 cells following tumor exposure, with higher-molecular weight fractions of the melanoma secretome as mediators. Notably, gal-9 depletion was mirrored with a reduction in gal-9 ligands on the cell surface, particularly GalNAc-containing glycoepitopes, pointing towards a melanoma-exploited gal-9-glycan axis as a DC-evasive strategy. Interestingly, restoring gal-9 surface levels in CM-exposed CD14cDC2 cells prevented the expansion of regulatory T cells (Tregs), postulating gal-9 as a novel immunomodulatory molecule in DC-mediated Treg induction during melanoma progression. Altogether, our data suggest that melanoma-derived factors remodel the DC glycan-gal-9 axis to enhance T cell differentiation towards regulatory phenotypes and dampen anti-tumor immunity. This identifies the gal-9/glycan axis in CD14cDC2 cells as a vulnerable node in melanoma immune evasion and as a potential therapeutic target.

immunology↗

Repeated shrimp allergen exposure drives 5-lipoxygenase-dependent avoidance and selective gut-brain activation

Peripheral immune processes can shape animal behavior, yet how noninfectious inflammatory reactions affect neural activity and behavioral outputs remains poorly understood. We developed an optimized murine model of shrimp allergy using whole shrimp extract to examine how a complex dietary allergen elicits integrated immune, neural, and behavioral responses. Sensitized mice received repeated oral shrimp challenges and were assessed for allergic pathology, food preference, affective-like behaviors, and neuronal activation in the brain. Repeated exposure increased total IgE and shrimp-specific IgG1, induced mast cell activation, accelerated gastrointestinal transit, caused mild hypothermia consistent with oral anaphylaxis, and increased intestinal length. Shrimp-sensitized mice did not avoid shrimp solution after sensitization alone. Instead, avoidance emerged only after repeated oral challenges and strengthened over time. This delayed aversion occurred without detectable changes in locomotor activity or measures of anxiety-like or depressive-like behavior at the time points tested. Repeated shrimp exposure increased cFOS expression in the area postrema, nucleus of the tractus solitarius, central amygdala, and paraventricular nucleus of the thalamus, implicating brainstem and limbic-thalamic pathways involved in visceral sensing and aversion. Pharmacological inhibition of 5-lipoxygenase partially reversed avoidance and reduced circulating mast cell protease-1 in allergic mice. These findings establish a robust whole-shrimp allergy model and show that a complex food allergen engages gut-brain pathways to promote 5-lipoxygenase-dependent avoidance. The delayed, selective nature of this response supports immune-mediated food aversion as a shared output of food allergy, while suggesting that its kinetics and neural recruitment vary with allergen identity and inflammatory context.

immunology↗

Targeting IL-2 to inflamed tissues via oxidation-specific epitopes enables third-generation bispecific IL-2 therapeutics

Interleukin-2 (IL-2) is essential for the survival and activation of regulatory T cells (Tregs). Low-dose native IL-2 (IL-2LD) therapy restores immune regulation in vivo and has shown reproducible clinical benefit across multiple autoimmune, inflammatory, and neuroimmune diseases. Attempts to improve IL-2 through engineered variants (muteins) have mainly focused on enhancing Treg selectivity by reducing IL-2 receptor {beta}-chain binding, but this strategy profoundly diminishes biological potency, likely contributing to the limited clinical efficacy of IL-2 muteins. Here, we develop a ''third-generation IL-2'' that combines site-specific targeting and bifunctionality. We generated a bivalent fusion protein linking IL-2 to a single-chain antibody recognizing oxidation-specific epitopes (OSEs), which are abundantly expressed at inflamed sites. Targeting OSEs provides not only site-specific localization, but also true bifunctionality as both anti-OSE antibodies and IL-2LD independently show therapeutic benefit in limiting inflammation. We first show that IL-2IT has bifunctional biological activities in vitro. In vivo, IL-2IT had increased specificity for Treg over Teff activation, which we attribute to a conformation-dependent modulation of IL-2 receptor engagement. Importantly, IL-2IT provided precise delivery to inflamed tissues in models of psoriasis and colitis. Altogether, this resulted in superior therapeutic benefit in multiple clinical settings, including in atherosclerosis models. Thus, our strategy illustrates a generalizable approach to cytokine engineering that preserves native signaling while achieving spatial control. Specifically, our findings validate OSE targeting as an efficient strategy to guide therapeutics to sites of inflammation and establish OSE-IL-2 as a promising bispecific Treg engager for treating inflammation.

immunology↗